综述 |
|
|
|
|
用于筛选人工结合蛋白的骨架蛋白 |
袁丽, 戴和平 |
中国科学院水生生物研究所 淡水生态与生物技术国家重点实验室 武汉 430072 |
|
Overview of Scaffold Protein Used for Selection of Artificial Binding Proteins |
YUAN Li, DAI He-ping |
State Key Laboratory of Freshwater Ecology and Biotechnology, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, China |
[1] Leader B, Baca Q J, Golan D E. Protein therapeutics: a summary and pharmacological classification. Nature Reviews Drug discovery, 2008, 7:21-39. [2] Ku J, Schultz P G. Alternate protein frameworks for molecular recognition. Proc Natl Acad Sci U S A, 1995, 92:6552-6556. [3] Lofblom J, Frejd F Y, Stahl S. Non-immunoglobulin based protein scaffolds. Curr Opin Biotechnol, 2011, 22:843-848. [4] Nygren P A, Skerra A. Binding proteins from alternative scaffolds. Journal of Immunological Methods, 2004, 290:3-28. [5] Hey T, Fiedler E, Rudolph R, et al. Artificial, non-antibody binding proteins for pharmaceutical and industrial applications. Trends Biotechnol, 2005, 23:514-522. [6] Binz H K, Amstutz P, Pluckthun A. Engineering novel binding proteins from nonimmunoglobulin domains. Nature Biotechnology, 2005, 23:1257-1268. [7] Gebauer M, Skerra A. Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol, 2009, 13:2452-2455. [8] 杜建芳, 王金凤, 孙万军, 等. 以Trx为骨架构建可诱导表达的酵母构象型随机肽库. 军事医学科学院院刊, 2006, 30 (3):201-205. Du J F, Wang J F, Sun W J, et al. Construct ion of an inducible yeast random conformat ion-constrained peptide library based on Trx scaffold. Bull Acad Mil Med Sci, 2006, 30 (3):201-205. [9] 赵安, 薛沿宁, 冯健男, 等. 昆虫防御素A的分子改造及其在噬菌体表面的展示. 军事医学院院刊, 2002, 26 (4):270-272. Zhao A, Xue Y N, Feng J N, et al. Rational design of the insect defensin A and its displaying on the surface of phage. Bull Acad Mil Med Sci, 2002, 26 (4):270-272. [10] Reichert J M, Valge-Archer V E. Development trends for monoclonal antibody cancer therapeutics. Nature Reviews Drug Discovery, 2007, 6:349-356. [11] Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 1975, 256:495-497. [12] Smith G P. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science, 1985, 228:1315-1317. [13] McCafferty J, Griffiths A D, Winter G, et al. Phage antibodies: filamentous phage displaying antibody variable domains. Nature, 1990, 348:552-524. [14] Ebersbach H, Fiedler E, Scheuermann T, et al. Affilin-novel binding molecules based on human gamma-B-crystallin, an All beta-Sheet Protein. J Mol Biol, 2007, 372:172-185. [15] Hackel B J, Kapila A, Wittrup K D. Picomolar affinity fibronectin domains engineered utilizing loop length diversity, recursive mutagenesis, and loop shuffling. J Mol Biol, 2008, 381:1238-1252. [16] Koide A, Abbatiello S, Rothgery L, et al. Probing protein conformational changes in living cells by using designer binding proteins: application to the estrogen receptor. Proc Natl Acad Sci U S A, 2002, 99:1253-1258. [17] Amstutz P, Binz H K, Parizek P, et al. Intracellular kinase inhibitors selected from combinatorial libraries of designed ankyrin repeat proteins. J Biol Chem, 2005, 280:24715-24722. [18] Roberts B L, Markland W, Ley A C, et al. Directed evolution of a protein: selection of potent neutrophil elastase inhibitors displayed on M13 fusion phage. Proc Natl Acad Sci U S A, 1992, 89:2429-2433. [19] Dennis M S, Herzka A, Lazarus R A. Potent and selective Kunitz domain inhibitors of plasma kallikrein designed by phage display. J Biol Chem, 1995, 270:25411-25417. [20] Williams A, Baird L G. DX-88 and HAE: a developmental perspective. Transfus Apher Sci, 2003, 29:255-258.. [21] Wark P A. DX-890 (Dyax). IDrugs: the investigational drugs journal, 2002, 5:586-589. [22] Baggio R, Burgstaller P, Hale S P, et al. Identification of epitope-like consensus motifs using mRNA display. J Mol Recognit, 2002, 15:126-134. [23] Hilpert K, Wessner H, Schneider-Mergener J, et al. Design and characterization of a hybrid miniprotein that specifically inhibits porcine pancreatic elastase. J Biol Chem, 2003, 278:24986-24993. [24] Christmann A, Walter K, Wentzel A, et al. The cystine knot of a squash-type protease inhibitor as a structural scaffold for Escherichia coli cell surface display of conformationally constrained peptides. Protein Engineering, 1999, 12:797-806. [25] Skerra A. Alternative binding proteins: anticalins - harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities. FEBS J, 2008, 275:2677-2683. [26] Gebauer M, Skerra A. Anticalins small engineered binding proteins based on the lipocalin scaffold. Methods Enzymol, 2012, 503:157-188. [27] Hohlbaum A M, Skerra A. Anticalins: the lipocalin family as a novel protein scaffold for the development of next-generation immunotherapies. Expert Review of Clinical Immunology, 2007, 3:491-501. [28] Liu J, Ning B, Liu M, et al. Construction of ribosome display library based on lipocalin scaffold and screening anticalins with specificity for estradiol. The Analyst, 2012, 137:2470-2479. [29] Mercader J V, Skerra A. Generation of anticalins with specificity for a nonsymmetric phthalic acid ester. Anal Biochem, 2002, 308:269-277. [30] Schlehuber S, Skerra A. Anticalins as an alternative to antibody technology. Expert Opinion on Biological Therapy, 2005, 5:1453-1462. [31] Schonfeld D, Matschiner G, Chatwell L, et al. An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies. Proc Natl Acad Sci U S A, 2009, 106:8198-8203. [32] Kim H J, Eichinger A, Skerra A. High-affinity recognition of lanthanide(III) chelate complexes by a reprogrammed human lipocalin 2. J Am Chem Soc, 2009, 131:3565-3576. [33] Schlehuber S, Skerra A. Anticalins in drug development. BioDrugs: clinical immunotherapeutics. Biopharmaceuticals and Gene Therapy, 2005, 19:279-288. [34] Hufton S E, van Neer N, van den Beuken T, et al. Development and application of cytotoxic T lymphocyte-associated antigen 4 as a protein scaffold for the generation of novel binding ligands. FEBS letters, 2000, 475:225-231. [35] Irving R A, Coia G, Roberts A, et al. Ribosome display and affinity maturation: from antibodies to single V-domains and steps towards cancer therapeutics. Journal of Immunological Methods, 2001, 248:31-45. [36] Koide A, Bailey C W, Huang X, et al. The fibronectin type III domain as a scaffold for novel binding proteins. J Mol Biol, 1998, 284:1141-1151. [37] Binz H K, Amstutz P, Kohl A, et al. High-affinity binders selected from designed ankyrin repeat protein libraries. Nature Biotechnology, 2004, 22:575-582. [38] Tamaskovic R, Simon M, Stefan N, et al. Designed ankyrin repeat proteins (DARPins) from research to therapy. Methods Enzymol, 2012, 503:101-134. [39] Binz H K, Stumpp M T, Forrer P, et al. Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. J Mol Biol, 2003, 332:489-503. [40] Boersma Y L, Pluckthun A. DARPins and other repeat protein scaffolds: advances in engineering and applications. Curr Opin Biotechnol, 2011, 22:849-857. [41] Seeger M A, Mittal A, Velamakanni S, et al. Tuning the drug efflux activity of an ABC transporter in vivo by in vitro selected DARPin binders. PLoS One, 2012, 7:e37845. [42] Steiner D, Forrer P, Pluckthun A. Efficient selection of DARPins with sub-nanomolar affinities using SRP phage display. J Mol Biol, 2008, 382:1211-1227. [43] Stumpp M T, Binz H K, Amstutz P. DARPins: a new generation of protein therapeutics. Drug Discovery Today, 2008, 13:695-701. [44] Nord K, Nilsson J, Nilsson B, et al. A combinatorial library of an alpha-helical bacterial receptor domain. Protein Engineering, 1995, 8:601-608. [45] Nord K, Gunneriusson E, Ringdahl J, et al. Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. Nature Biotechnology, 1997, 15:772-777. [46] Wahlberg E, Lendel C, Helgstrand M, et al. An affibody in complex with a target protein: structure and coupled folding. Proc Natl Acad Sci U S A, 2003, 100:3185-190. [47] Mirecka E A, Hey T, Fiedler U, et al. Affilin molecules selected against the human papillomavirus E7 protein inhibit the proliferation of target cells. J Mol Biol, 2009, 390:710-721. [48] Hoffmann A, Kovermann M, Lilie H, et al. New binding mode to TNF-alpha revealed by ubiquitin-based artificial binding protein. PLoS One, 2012, 7:e31298. [49] Nilsson B, Berman-Marks C, Kuntz I D, et al. Secretion incompetence of bovine pancreatic trypsin inhibitor expressed in Escherichia coli. J Biol Chem, 1991, 266:2970-2977. [50] Teter S A, Klionsky D J. How to get a folded protein across a membrane. Trends in Cell Biology, 1999, 9:428-431. [51] Valent Q A. Signal recognition particle mediated protein targeting in Escherichia coli. Antonie van Leeuwenhoek, 2001, 79:17-31. [52] Nangola S, Minard P, Tayapiwatana C. Appraisal of translocation pathways for displaying ankyrin repeat protein on phage particles. Protein Expression and Purification, 2010, 74:156-161. [53] Steiner D, Forrer P, Stumpp M T, et al. Signal sequences directing cotranslational translocation expand the range of proteins amenable to phage display. Nature Biotechnology, 2006, 24:823-831. [54] Droge M J, Boersma Y L, Braun P G, et al. Phage display of an intracellular carboxylesterase of Bacillus subtilis: comparison of Sec and Tat pathway export capabilities. Applied and Environmental Microbiology, 2006, 72:4589-4595. [55] Velappan N, Fisher H E, Pesavento E, et al. A comprehensive analysis of filamentous phage display vectors for cytoplasmic proteins: an analysis with different fluorescent proteins. Nucleic Acids Res, 2010, 38:e22. [56] Paschke M, Hohne W. A twin-arginine translocation (Tat)-mediated phage display system. Gene, 2005, 350:79-88. [57] Speck J, Arndt K M, Muller K M. Efficient phage display of intracellularly folded proteins mediated by the TAT pathway. Protein Eng Des Sel, 2011, 24:473-484. [58] Krumpe L R, Atkinson A J, Smythers G W, et al. T7 lytic phage-displayed peptide libraries exhibit less sequence bias than M13 filamentous phage-displayed peptide libraries. Proteomics, 2006, 6:4210-4222. [59] Herman R E, Badders D, Fuller M, et al. The Trp cage motif as a scaffold for the display of a randomized peptide library on bacteriophage T7. J Biol Chem, 2007, 282:9813-9824. [60] Dai M, Temirov J, Pesavento E, et al. Using T7 phage display to select GFP-based binders. Protein Eng Des Sel, 2008, 21:413-424. [61] Beck A, Wurch T, Bailly C, et al. Strategies and challenges for the next generation of therapeutic antibodies. Nature Reviews Immunology, 2010, 10:345-352. [62] Tolmachev V. Imaging of HER-2 overexpression in tumors for guiding therapy. Current Pharmaceutical Design, 2008, 14:2999-3019. [63] Miao Z, Levi J, Cheng Z. Protein scaffold-based molecular probes for cancer molecular imaging. Amino Acids, 2011, 41:1037-1047. [64] Sennhauser G, Grutter M G. Chaperone-assisted crystallography with DARPins. Structure, 2008, 16:1443-1453. [65] Huber T, Steiner D, Rothlisberger D, et al. In vitro selection and characterization of DARPins and Fab fragments for the co-crystallization of membrane proteins: The Na(+)-citrate symporter CitS as an example. J Struct Biol, 2007, 159:206-221. [66] Nord K, Gunneriusson E, Uhlen M, et al. Ligands selected from combinatorial libraries of protein A for use in affinity capture of apolipoprotein A-1M and taq DNA polymerase. Journal of Biotechnology, 2000, 80:45-54. [67] Reina J, Lacroix E, Hobson S D, et al. Computer-aided design of a PDZ domain to recognize new target sequences. Nature Structural Biology, 2002, 9:621-627. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|